Latest Articles

Publication Date
Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer - OncLive

Dr Vetter on the Role of Trial Inclusion Criteria on Coverage for Pembrolizumab- and Dostarlimab-Based Regimens in Endometrial Cancer OncLive

Published: Jan. 20, 2025, 9:34 p.m.
5 actions to boost women's health and the global economy - World Economic Forum

5 actions to boost women's health and the global economy World Economic Forum

Published: Jan. 20, 2025, 8:05 p.m.
Bindi Irwin Says She Has A Second Chance In Life - imdb

Bindi Irwin Says She Has A Second Chance In Life imdb

Published: Jan. 20, 2025, 5:38 p.m.
Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer - Cancer Network

Dostarlimab Combo Earns Expanded European Approval in Endometrial Cancer Cancer Network

Published: Jan. 20, 2025, 5:08 p.m.
Orexo converts vipoglanstat royalties into Gesynta stake - The Pharma Letter

Orexo converts vipoglanstat royalties into Gesynta stake The Pharma Letter

Published: Jan. 20, 2025, 4:47 p.m.
Bindi Irwin Says She Has A Second Chance In Life - TV Shows Ace

Bindi Irwin Says She Has A Second Chance In Life TV Shows Ace

Published: Jan. 20, 2025, 4:25 p.m.
Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone - Taste of Country

Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone Taste of Country

Published: Jan. 20, 2025, 3:41 p.m.
Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone - catcountry1073.com

Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone catcountry1073.com

Published: Jan. 20, 2025, 3:41 p.m.
Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone - K99

Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone K99

Published: Jan. 20, 2025, 3:41 p.m.
Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone - LoneStar 92.3

Bindi Irwin Cried ‘Happy Tears’ Over This Health Milestone LoneStar 92.3

Published: Jan. 20, 2025, 3:41 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!